Condensed Consolidated Interim Financial Statements as of June 30, 2016

Bayer Group
Consolidated Income Statements

 

 

Q2 2015

Q2 2016

 

H1 2015

H1 2016

 

 

€ million

€ million

 

€ million

€ million

2015 figures restated

1

EBIT = income after income taxes, plus income taxes, plus financial result

Net sales

 

12,003

11,833

 

23,796

23,687

Cost of goods sold

 

(5,267)

(5,028)

 

(10,703)

(10,072)

Gross profit

 

6,736

6,805

 

13,093

13,615

Selling expenses

 

(3,147)

(3,092)

 

(6,044)

(5,980)

Research and development expenses

 

(1,035)

(1,122)

 

(1,979)

(2,231)

General administration expenses

 

(548)

(489)

 

(1,018)

(984)

Other operating income

 

31

159

 

278

362

Other operating expenses

 

(214)

(123)

 

(582)

(324)

EBIT1

 

1,823

2,138

 

3,748

4,458

Equity-method loss

 

(6)

(6)

 

(11)

Financial income

 

85

42

 

97

79

Financial expenses

 

(366)

(350)

 

(658)

(697)

Financial result

 

(287)

(314)

 

(561)

(629)

Income before income taxes

 

1,536

1,824

 

3,187

3,829

Income taxes

 

(390)

(431)

 

(759)

(905)

Income from continuing operations after income taxes

 

1,146

1,393

 

2,428

2,924

Income from discontinued operations after income taxes

 

24

55

 

82

105

Income after income taxes

 

1,170

1,448

 

2,510

3,029

of which attributable to noncontrolling interest

 

6

68

 

12

138

of which attributable to Bayer AG stockholders (net income)

 

1,164

1,380

 

2,498

2,891

 

 

 

 

 

 

 

 

 

in €

in €

 

in €

in €

Earnings per share

 

 

 

 

 

 

From continuing operations

 

 

 

 

 

 

Basic

 

1.38

1.60

 

2.92

3.37

Diluted

 

1.38

1.60

 

2.92

3.37

From discontinued operations

 

 

 

 

 

 

Basic

 

0.02

0.07

 

0.10

0.13

Diluted

 

0.02

0.07

 

0.10

0.13

From continuing and discontinued operations

 

 

 

 

 

 

Basic

 

1.40

1.67

 

3.02

3.50

Diluted

 

1.40

1.67

 

3.02

3.50